Health and Healthcare
Mannkind Sinks on Afrezza License Termination
Published:
Last Updated:
MannKind Corp. (NASDAQ: MNKD) is one of the most traded biotech companies on the market, and one of the most shorted as well. In Tuesday’s session the stock took a big downturn after the company decided to terminate its insulin inhaler project with Sanofi-Aventis.
MannKind announced the termination of its license and collaboration agreement with Sanofi U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. Both parties promptly will commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 to 180 days.
In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi’s notice of termination, or July 4, 2016.
Over the course of the past 52 weeks MannKind, has vastly underperformed the market, with the stock down nearly 75%.
As of the most recent short interest settlement date, MannKind’s short interest totaled 111.52 million shares with 19 days to cover.
Tuesday morning, shares of MannKind fell to a new 52-week low of $0.96. The consensus analyst price target is $4.80, and the 52-week high is $7.88.
Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
